A Phase 2, Open Label Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon and Ribavirin in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1.

Trial Profile

A Phase 2, Open Label Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon and Ribavirin in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs BIT 225 (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Adverse reactions
  • Sponsors Biotron
  • Most Recent Events

    • 10 Oct 2014 Results published in Biotron media release.
    • 21 Nov 2013 Interim results published in Biotron media release.
    • 21 Nov 2013 Status changed from active, no longer recruiting to completed, according to a Biotron media release. The trial was completed in mid-2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top